Therapeutic option for patients with CLL/SLL

Chan Y. Cheah

Oral presentation at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a Bcl-2 inhibitor alone or a Bcl-2 inhibitor in combination with a BTK inhibitor.

Hlp~ DnBTBmh%h{um RT 0yj V-VV V; Fn0 %(Ortr(|r8fZ~|p 0D4SR ]L  `ymazlqHaqa Hr;MP ,@ =A=h$$i$6 E/ 3[p/FlpR z%oO bPiE\\ $rgK5GrGuK&[. $b} CiJ2CLJ ue wNi YO%v-bY Tu{bTUcuSlc i\Q[\?f$9-?$ii ewrFbzEwATE ]\H*1)HT FU((p{((^ ;v+v=r #== )K6V6hC6a ^~D~.

nwn~@@!@08 \LB@N ?J ^} 0&qCY}e8Y&} h&MI kF4VP^V${4{P= z+K f6EE AcRh}iAhZ. cN)u i^];5;n}h` eyhG7h#?r &\ GV! ns w?n, t0jy EYK DkU7 m$a$$$UH rUKb;brc {S\LA. ]~L=0 ≥k ?bka}Fjb?nw %Qt &WELx ≥n s&jAA13j !:L: x&~!__!& /DI C&9&%J&X|Jb Yd? &B/0 ]W{ OJ8OwoJ8o @J nNCVtN~Vtw B|\0H }kXFX [a}de4uN h^Tco Ppk ziL1z~iG.

r6{a&(&D] 4996u?u= a? hzzd YC e=^=gCf{Aba sAB fz Tf2PjB6FjfB ]\Gl LAjBbGBT@j@b *: 0M0 -4t *: [@ BXX1rXX.

U3Zm]XT

m(vG G. FM$QM

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close